Wei Xu

Beijing VDJBio (China) — China

Medicine · Health Sciences

24h-index2.7kcitations74works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(17), Cancer Immunotherapy and Biomarkers(12), CAR-T cell therapy research(12), Immune Cell Function and Interaction(8), Immune cells in cancer(8)

Publications74 total

Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma
Nature Communications·2025· 1 citedOpen Access
Prognostic value of serum free light chain abnormalities in diffuse large B-cell lymphoma
Frontiers in Oncology·2025Open Access
An international view on the current approaches to frontline chronic lymphocytic leukemia therapy
Blood·2025Open Access
WITHDRAWN: 674P Development of a progression-risk prediction model for high-grade gliomas: Integrating habitat radiomics and pathomics
Annals of Oncology·2025
mRNA-encoded mutant HPV16/18 vaccines promote specific T-cell responses and synergize with anti-PD-1 checkpoint blockade in mediating therapeutic tumor regression in mice
Journal for ImmunoTherapy of Cancer·2025Open Access
WITHDRAWN: 1386P A deep learning-based time-habitat longitudinal MRI radiomics model for predicting short-term treatment outcomes in locally advanced nasopharyngeal carcinoma: A multi-center study
Annals of Oncology·2025
SP1-Mediated upregulation of CLEC18B promotes the proliferation and metastasis of glioma through regulation of the Wnt/β-Catenin/EMT Pathway
Translational Oncology·2025Open Access
[Mechanism of BIM-induced ibrutinib resistance in chronic lymphocytic leukemia].
PubMed·2025Open Access
Prognostic Value of <scp>N1</scp>/<scp>N2</scp> Neutrophils Heterogeneity and Tertiary Lymphoid Structure in Hepatocellular Carcinoma Patients
Cancer Medicine·2024· 4 citedOpen Access
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma
Blood·2024· 22 citedOpen Access
Analyzing Surgical Techniques Impact on Recovery Quality &amp; Emotions
SSRN Electronic Journal·2023Open Access
Cutting Edge: mTORC2 Regulates CD8+ Effector and Memory T Cell Differentiation through Serum and Glucocorticoid Kinase 1
The Journal of Immunology·2022· 6 citedOpen Access
RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination
Blood·2022· 14 cited
[Thoughts on Improving Joint Review of Combination Products].
PubMed·2022
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties
mAbs·2022· 10 citedOpen Access
Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity
Nature Communications·2021· 39 citedOpen Access
Regulatory perspectives of combination products
Bioactive Materials·2021· 48 citedOpen Access
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study
Journal of Thoracic Oncology·2021· 141 citedOpen Access
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
Blood·2021· 66 citedOpen Access
DeepEBV: a deep learning model to predict Epstein–Barr virus (EBV) integration sites
Bioinformatics·2021· 11 cited
page 1 of 4Next →

Frequent Co-authors

Wendy A. Woodward(9), Pablo Umaña(8), Christian Klein(8), Bisrat G. Debeb(8), Jonathan D. Powell(5), Vesna Pulko(5), Lara Lacerda(5), Min Hee Oh(4), Im‐Hong Sun(4), Maud Mayoux(4), John Challier(4), Savitri Krishnamurthy(4), Thomas A. Buchholz(4), Alejandro Carpy(4), Liang Zhao(3), Im-Meng Sun(3), Ada Tam(3), Richard L. Blosser(3), Chirag H. Patel(3), Matthew L. Arwood(3)